These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective. Mody H; Ogasawara K; Zhu X; Miles D; Shastri PN; Gokemeijer J; Liao MZ; Kasichayanula S; Yang TY; Chemuturi N; Gupta S; Jawa V; Upreti VV Clin Pharmacol Ther; 2023 Sep; 114(3):530-557. PubMed ID: 37393588 [TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacology Considerations for the "Off-the-Shelf" Allogeneic Cell Therapies. Mody H; Sutaria DS; Miles D Clin Pharmacol Ther; 2024 Jun; 115(6):1233-1250. PubMed ID: 38501153 [TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches. Chaudhury A; Zhu X; Chu L; Goliaei A; June CH; Kearns JD; Stein AM J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S147-S159. PubMed ID: 33205434 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386 [TBL] [Abstract][Full Text] [Related]
7. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Qi T; McGrath K; Ranganathan R; Dotti G; Cao Y Adv Drug Deliv Rev; 2022 Sep; 188():114421. PubMed ID: 35809868 [TBL] [Abstract][Full Text] [Related]
9. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy. Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554 [TBL] [Abstract][Full Text] [Related]
10. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective. Lin X; Lee S; Sharma P; George B; Scott J J Clin Oncol; 2022 Oct; 40(30):3501-3509. PubMed ID: 35613410 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Thibodeaux SR; Milone MC Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467 [TBL] [Abstract][Full Text] [Related]
12. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies. Rallis KS; Hillyar CRT; Sideris M; Davies JK Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705 [TBL] [Abstract][Full Text] [Related]
13. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL MAbs; 2020; 12(1):1688616. PubMed ID: 31852337 [TBL] [Abstract][Full Text] [Related]
14. CAR T Cell Therapy for Hematological Malignancies. Yang X; Wang GX; Zhou JF Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217 [TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives. Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980 [TBL] [Abstract][Full Text] [Related]
16. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Zhang E; Gu J; Xu H Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591 [TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
19. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215 [TBL] [Abstract][Full Text] [Related]
20. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists? Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]